Genomic Valley Biotech Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2016 - 2020
Net Income	3.56	0.15	6.48	-0.09	-5.59	Upgrade
Depreciation & Amortization	0.03	0.01	0.08	0.84	1.89	Upgrade
Loss (Gain) From Sale of Assets	-	-	-	-4.19	-	Upgrade
Other Operating Activities	-0.04	-0.02	2.22	-3.33	0.57	Upgrade
Change in Accounts Receivable	3.16	-3.13	-22.17	0.65	0.38	Upgrade
Change in Inventory	-2.84	-	-	-	1.24	Upgrade
Change in Other Net Operating Assets	-3.59	2.78	5.6	-15.17	16.36	Upgrade
Operating Cash Flow	0.27	-0.2	-7.79	-21.29	14.85	Upgrade
Operating Cash Flow Growth	-	-	-	-	239.44%	Upgrade
Capital Expenditures	-0.09	-	-	-	-15.79	Upgrade
Sale of Property, Plant & Equipment	-	-	14.79	53.46	-	Upgrade
Investment in Securities	0.17	-0.17	-	-	-	Upgrade
Other Investing Activities	0.04	0.02	0.43	-16.78	-0	Upgrade
Investing Cash Flow	0.12	-0.15	15.22	36.68	-15.79	Upgrade
Long-Term Debt Issued	-	-	-	-	0.68	Upgrade
Long-Term Debt Repaid	-	-	-7.05	-15.47	-	Upgrade
Net Debt Issued (Repaid)	-	-	-7.05	-15.47	0.68	Upgrade
Financing Cash Flow	-	-	-7.05	-15.47	0.68	Upgrade
Miscellaneous Cash Flow Adjustments	-	0	-	-	-	Upgrade
Net Cash Flow	0.39	-0.35	0.39	-0.09	-0.26	Upgrade
Free Cash Flow	0.18	-0.2	-7.79	-21.29	-0.95	Upgrade
Free Cash Flow Margin	2.09%	-12.16%	-28.60%	-3017.82%	-45.45%	Upgrade
Free Cash Flow Per Share	0.06	-0.07	-2.55	-6.84	-0.31	Upgrade
Cash Income Tax Paid	0.85	-	-	-	-	Upgrade
Levered Free Cash Flow	2.6	-4.6	-1.7	-18.68	-13.86	Upgrade
Unlevered Free Cash Flow	2.6	-4.6	-1.7	-18.41	-12.75	Upgrade
Change in Working Capital	-3.27	-0.35	-16.57	-14.52	17.97	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.